Both clinical and genetic heterogeneity in the VMD phenotype have been reported. Although the disease is usually bilateral with a single lesion in the central macula, unilateral cases have been described,
8 and multifocal disease
9 can also occur. Pathogenic variants in
BEST1,
PRPH2,
IMPG1, and
IMPG2 have all been associated with VMD, with
BEST1 noted most commonly. The expression of these genes is thought to differ across cell types (e.g., photoreceptors, RPE cells). The
BEST1 gene [Mendelian Inheritance in Man (MIM) #607854] encodes a bestrophin family protein expressed in RPE cells
10 that is believed to function as an anion channel and intracellular calcium signaling regulator
11,12 and is the gene most often associated with VMD.
13,14 In the case of
BEST1 related disease, dysfunction of the bestrophin protein leads to a weakened RPE-photoreceptor interface and formation of vitelliform deposits,
15 but histopathology has suggested that the affected area extends beyond the clinically-evident lesion.
16,17 Less commonly,
PRPH2 (MIM #179605),
IMPG1 (MIM #602870), and
IMPG2 (MIM #607056) have also been associated with VMD,
18–20 but the pathophysiology of vitelliform lesion development in these conditions is not well established.
PRPH2, peripherin-2, encodes a tetraspanin transmembrane protein that localizes to the rims of cone lamellae and rod disks, where it helps maintain the structure and function of photoreceptor outer segments.
21,22 In addition to VMD,
PRPH2 is also associated with other retinal phenotypes including pattern macular dystrophy.
18 Finally,
IMPG1 (MIM #602870) and
IMPG2 (MIM #607056) encode two interphotoreceptor matrix proteoglycans that are important for the cone-specific glycocalyx and extracellular matrix surrounding cones.
23 Elucidating the cellular pathophysiology of VMD with respect to these different genes is an important first step toward unraveling the mechanisms of VMD.